# Artificial Intelligence In Genomics Market

> Artificial Intelligence in Genomics Market Research Report By Application (Drug Discovery, Genetic Testing, Personalized Medicine, Agrigenomics, Clinical Diagnostics), By Technology (Machine Learning, Deep Learning, Natural Language Processing, Reinforcement Learning, Computer Vision), By End User (Pharmaceutical Companies, Research Institutes, Healthcare Providers, Biotechnology Companies), By Deployment Mode (On-Premises, Cloud-Based, Hybrid) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 33.46%
- **2024:** $ 4.23 Billion
- **2025:** $ 5.65 Billion
- **2035:** $ 101.24 Billion
- **Key Players:** Companies such as Illumina (US), Thermo Fisher Scientific (US), Bristol-Myers Squibb (US), GRAIL (US), IBM (US), Deep Genomics (CA), Freenome (US), XtalPi (CN), Genomatix (DE) are some of the major participants in the market.

**Report ID:** MRFR/HC/20633-HCR · **Pages:** 100 · **Author:** Satyendra Maurya & Rahul Gotadki · **Last Updated:** May 07, 2026

**URL:** https://www.marketresearchfuture.com/reports/artificial-intelligence-in-genomics-market-22233

---

## Market Summary

## **Global Artificial Intelligence in Genomics Market Summary**

As per MRFR analysis, the artificial intelligence in genomics market size was estimated at 2.35 (USD billion) in 2024 and is expected to grow to 25 (USD billion) by 2035 at a CAGR (growth rate) of around 23.98% during the forecast period (2025-2035).

**Key Market Trends and Highlights**

In the Artificial Intelligence in Genomics Market, North America holds the largest market share valued at 0.94 USD Billion in 2024.

- The artificial intelligence in genomics market in Europe is expected to be valued at 8.05 USD Billion by 2035
- The personalized medicine segment was valued at 0.5 USD billion in the artificial intelligence in genomics market in 2024.
- The market value for drug discovery is projected to reach 8.0 USD billion by 2035.
- Advancements in genomics research and development of precision medicine will mostly enhance scope for AI in genomics.

**Major Players**

Key artificial intelligence in genomics market players include Thermo Fisher Scientific, iCarbonX, Grail, and other players. Players incorporate artificial intelligence to enhance data interpretation, improve accuracy in genomic sequencing, and streamline workflows in genomic laboratories.

**Market Size, Forecast and Growth Rate**

2024 Market Size: USD 2.35 Billion

2035 Market Size: USD 25 Billion

CAGR 2025 to 2035: 23.98%

Largest Regional Market Share in 2024: North America

**Key Artificial Intelligence in Genomics Market Trends Highlighted**

The Artificial Intelligence in Genomics Market is experiencing significant growth driven by several key market drivers. Increased investment in research and development, particularly in the life sciences sector, has fueled the integration of AI technologies into genomic analyses. This is largely due to the growing demand for personalized medicine, which aims to tailor treatment plans based on individual genetic profiles. As healthcare systems shift towards precision medicine, AI is playing a vital role in processing large amounts of genomic data, thereby enhancing diagnostic accuracy and treatment efficacy. 

The potential for exploration in this market is extensive, especially regarding partnerships between technology companies and healthcare organizations. By harnessing shared knowledge, these collaborations can expedite advancements in AI algorithms tailored for genomic analysis. Furthermore, governments worldwide are acknowledging the significance of genomics in public health and are channeling resources into infrastructure to support genomic research. These initiatives can open new pathways for AI applications in genomics, particularly in areas like disease prevention and population health management.

Recently, trends in the global market indicate a significant uptick in the adoption of machine learning algorithms and natural language processing tools in genomics research and clinical applications. Research institutions and healthcare providers are increasingly utilizing these advanced technologies to streamline genomic data interpretation and improve patient outcomes. The rising pressure to reduce healthcare costs while enhancing quality of care is also propelling the demand for efficient AI solutions in genomics.

Overall, the synergy between AI advancements and genomics is paving the way for transformative changes in healthcare and research on a global scale, hinting at a promising future for this market.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Artificial Intelligence in Genomics Market Drivers**

**Increasing Demand for Precision Medicine**

The Artificial Intelligence in Genomics Market is experiencing significant growth driven by the rising demand for precision medicine. Precision medicine tailors treatment to individuals based on their genetic makeup, which is particularly crucial in oncology. The National Cancer Institute highlights that cancer cases are expected to rise to 23.6 million by 2030, an increase from 18.1 million in 2018. Organizations like GRAIL and Foundation Medicine are leveraging Artificial Intelligence and genomic sequencing to develop targeted therapies, improving success rates in cancer treatment.

Governments around the globe are now investing in genomics initiatives, with the U.S. National Institutes of Health launching the All of Us Research Program, aimed at advancing the use of genomic data for personalized healthcare solutions. This increasing focus on precision medicine is a key driver of growth in the Artificial Intelligence in Genomics Market.

**Advancements in Genomic Research and Technology**

The continuous advancements in genomic research and technology underpin the growth of the Artificial Intelligence in Genomics Market. The decreasing cost of genomic sequencing, which has fallen from approximately $100,000 in the early 2000s to less than $1,000 today, enables wider adoption among healthcare providers and researchers. This trend is supported by organizations like Illumina, which leads the market with innovative sequencing platforms.

The development of technologies such as CRISPR and next-generation sequencing fosters a greater understanding of the human genome. The World Economic Forum recently reported that genomic data is projected to double every seven months, emphasizing the need for sophisticated AI tools to analyze this volume of data effectively. This dynamic environment contributes significantly to the market's growth trajectory.

**Rising Incidence of Genetic Disorders**

The increasing incidence of genetic disorders is a significant driver for the Artificial Intelligence in Genomics Market. According to the World Health Organization, genetic disorders contribute to nearly 30% of deaths among children under the age of five, which highlights the urgent need for effective diagnostic and therapeutic solutions. Organizations like Genomics England and the European Society of Human Genetics are actively engaged in research and innovation aimed at identifying and treating genetic conditions.

By utilizing artificial intelligence, researchers can analyze genomic data to pinpoint mutations and predispositions to genetic disorders more efficiently. The elevated need for effective health solutions in this area propels demand for AI technologies in genomics, thus driving market growth.

**Artificial Intelligence in Genomics Market Segment Insights**

**Artificial Intelligence in Genomics Market Application Insights**

The Artificial Intelligence in Genomics Market by application encompasses areas such as drug discovery, genetic testing, personalized medicine, agrigenomics, and clinical diagnostics. Drug discovery is anticipated to hold a majority share, valued at 0.75 USD billion in 2024, and growing to 8.0 USD billion by 2035. It is vital for the pharmaceutical industry as it integrates AI technologies to streamline the drug development process, thus enhancing efficiency and reducing time-to-market for new therapies.

Genetic testing also represents a notable area in the market, expected to grow from 0.45 USD billion in 2024 to 5.0 USD billion in 2035. This application plays a significant role in identifying genetic disorders and informing treatment strategies, thereby driving demand for AI capabilities in genomics. Personalized medicine, with a valuation of 0.5 USD billion in 2024 and a forecasted increase to 6.0 USD billion by 2035, leverages AI for tailoring individualized treatments based on genetic makeup, making it a promising sub-segment that resonates with current trends towards customized healthcare solutions.

Agrigenomics is projected to grow from 0.3 USD billion in 2024 to 3.5 USD billion in 2035, emphasizing the application of genomics in agriculture to improve crop yield and resilience, which is increasingly critical given global food security challenges. Clinical diagnostics, valued at 0.35 USD billion in 2024 and expected to rise to 2.5 USD billion by 2035, facilitates faster and more accurate analysis of genetic information, thereby supporting enhanced patient care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Artificial Intelligence in Genomics Market Technology Insights**

By technology, the Artificial Intelligence in Genomics Market is experiencing significant growth, driven by the increasing demand for advanced data analysis in genomics. Machine learning and deep learning are critical components, as they enable the analysis of complex biological data, leading to improved diagnostics and personalized medicine.

Natural language processing plays a vital role in interpreting vast amounts of unstructured genomic data, facilitating better decision-making in research and clinical settings. Reinforcement learning is significant for optimizing genomic processes, such as drug discovery and clinical trial design. Computer vision is increasingly important, allowing researchers to analyze genomic images and structure variations with greater accuracy.

These technologies are not only enhancing the efficiency of genomic studies but also driving innovations in healthcare, making the Artificial Intelligence in Genomics Market a focal point for growth and development in the coming years. The market growth is supported by advancements in research, rising investments, and a strong emphasis on data-driven decision-making in the health sector.

**Artificial Intelligence in Genomics Market End User Insights**

The Artificial Intelligence in Genomics Market by end user includes different entities including pharmaceutical companies, research institutes, healthcare providers, and biotechnology companies. Pharmaceutical companies are particularly significant, leveraging AI for drug discovery and personalized medicine, thus streamlining Research and Development processes.

Research institutes are also playing a crucial role, engaging in cutting-edge genetic studies that enhance the understanding of genetic disorders. Healthcare providers are adopting AI solutions to improve patient outcomes by offering tailored treatments based on genomic insights. Biotechnology companies dominate the market due to their innovative approaches in using AI for genetic engineering and synthetic biology, which pave the way for novel therapeutic solutions.

The prevailing trend shows strong market expansion, driven by heightened investment in genomic research and innovations in AI technologies. Addressing challenges like data privacy and ethical concerns is crucial, yet there are numerous opportunities through collaborative R&D initiatives and developing regulatory frameworks that foster innovation in this vital sector.

**Artificial Intelligence in Genomics Market Deployment Mode Insights**

The Artificial Intelligence in Genomics Market by deployment mode is categorized primarily into on-premises, cloud-based, and hybrid deployment modes. On-premises solutions are preferred by organizations requiring greater control and security over sensitive genomic data, thereby maintaining compliance with stringent regulations.

Cloud-based deployments are gaining traction due to their scalability and flexibility, enabling facilities to manage large datasets without heavy infrastructure investments. The hybrid model, which combines elements of both on-premises and cloud solutions, is becoming increasingly popular as it allows institutions to effectively balance cost, performance, and data security.

**Artificial Intelligence in Genomics Market Regional Insights**

North America leads this market with a valuation of 0.94 USD billion in 2024 and is expected to expand to 10.73 USD billion by 2035, showcasing its dominance due to strong investments in health technology and research facilities. Europe follows closely, starting at 0.7 USD billion in 2024 and reaching 8.05 USD billion by 2035, reflecting robust research initiatives and collaborations among government and industry stakeholders.

South America, valued at 0.15 USD billion in 2024, is anticipated to grow to 1.75 USD billion by 2035, albeit with slower adoption rates due to less funding in technology. In Asia Pacific, a valuation of 0.5 USD billion in 2024 is expected to rise to 4.45 USD billion by 2035, supported by increasing investment in biotechnology and healthcare sectors, indicating significant growth potential. The Middle East and Africa begin with a valuation of 0.06 USD billion in 2024 and may reach 0.92 USD billion in 2035.

This lower figure highlights the emerging market opportunities in AI-driven genomics which may be further enhanced by increased government support and global collaborations.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

**Artificial Intelligence in Genomics Market Key Players and Competitive Insights**

The Artificial Intelligence in Genomics Market has garnered significant attention over recent years as innovations in AI technology enable new possibilities in genomic research and analysis. The competitive landscape is characterized by a diverse array of players ranging from established biotech firms to emerging tech companies. These entities are increasingly leveraging artificial intelligence to enhance data interpretation, improve accuracy in genomic sequencing, and streamline workflows in genomic laboratories.

Companies are differentiating themselves not only through technological innovation but also by forming strategic partnerships, engaging in mergers and acquisitions, and expanding their service offerings to meet the evolving needs of researchers and healthcare institutions. As the demand for personalized medicine and genomic data analysis grows, the competitive dynamics will continue to evolve with an emphasis on cutting-edge research and application.

Thermo Fisher Scientific is a leading player in the Artificial Intelligence in Genomics Market, known for its robust portfolio of genomic solutions and advanced technologies. The company has established a strong market presence by effectively integrating AI with its extensive tools for sequencing, genotyping, and molecular analysis. Thermo Fisher Scientific's strength lies in its ability to deliver comprehensive solutions that cater to various stages of the genomic research workflow, from sample preparation to data analysis.

By investing in research and development, the company has been able to enhance its capabilities in machine learning and data analytics, thus improving the accuracy and efficiency of genomic tests. Furthermore, its global reach and established relationships with research institutions and healthcare providers enable Thermo Fisher Scientific to maintain a steady market position and continue driving advancements in genomic AI applications.

iCarbonX is an important biotechnology company based in Shenzhen, known for its integration of artificial intelligence with genomic and multi-omics data to provide personalized health insights. Established in 2015 by former BGI CEO Jun Wang, the company’s premier platform, Meum, employs AI to assess genomic, proteomic, and behavioral data, providing customized health recommendations. The organization specializes in creating AI-driven tools for data mining, predictive modeling, and visualization, establishing itself as a significant contributor to precision health and digital genomics.

Supported by prominent investors and strategic partnerships, iCarbonX has broadened its international footprint through initiatives such as the Digital Life Alliance, working alongside organizations like SomaLogic and PatientsLikeMe. The acquisition of Israel-based Imagu Vision Technologies has further enhanced its AI and image-processing capabilities, solidifying its position as a leader in the evolving landscape of AI in genomics.

**Key Companies in the Artificial Intelligence in Genomics Market Include**

- Thermo Fisher Scientific
- iCarbonX
- Grail
- Microsoft
- IBM
- NVIDIA
- Illumina
- DNAnexus
- Deep Genomics
- Fabric Genomics
- PathAI
- Freenome
- Verily Life Sciences
- Sema4
- BenevolentAI

**Artificial Intelligence in Genomics Market Developments**

Recent advancements in the Artificial Intelligence in Genomics Market highlight remarkable progress and creativity. Organizations such as Thermo Fisher Scientific and Illumina are enhancing their AI-driven platforms to improve genomic sequencing and analysis, with Illumina utilizing DRAGEN for faster variant calling and data interpretation.

In July 2023, Illumina introduced the Alliance for Genomic Discovery, a collaborative initiative involving deCODE genetics (an Amgen subsidiary), AbbVie, AstraZeneca, Bayer, and Merck. This partnership aims to co-fund whole-genome sequencing of 250,000 diverse samples for the purpose of drug target discovery.

Microsoft has been enhancing its involvement in the biotech sector, particularly through a partnership with 1910 Genetics in June 2023 to implement Azure Quantum Elements for AI-driven drug discovery. Additionally, Amgen’s deCODE genetics started utilizing NVIDIA’s BioNeMo supercomputer in early 2024 to develop extensive genomic models (“Freyja”) aimed at biomarker and target discovery.

In recent years, there has been a surge of interest in AI-powered genomics, particularly following the launch of Grail's Galleri multi-cancer early-detection blood test in late 2022, which represents a significant advancement in AI-driven diagnostic applications.

**Artificial Intelligence In Genomics Market Segmentation Insights**

**Artificial Intelligence in Genomics Market Application Outlook**

- Drug Discovery
- Genetic Testing
- Personalized Medicine
- Agrigenomics
- Clinical Diagnostics

**Artificial Intelligence in Genomics Market Technology Outlook**

- Machine Learning
- Deep Learning
- Natural Language Processing
- Reinforcement Learning
- Computer Vision

**Artificial Intelligence in Genomics Market End User Outlook**

- Pharmaceutical Companies
- Research Institutes
- Healthcare Providers
- Biotechnology Companies

**Artificial Intelligence in Genomics Market Deployment Mode Outlook**

- On-Premises
- Cloud-Based
- Hybrid

**Artificial Intelligence in Genomics Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Emergence of Cloud Computing Solutions

The rise of cloud computing solutions is transforming the Artificial Intelligence in Genomics Market. Cloud platforms provide scalable resources for storing and analyzing large genomic datasets, making advanced AI tools more accessible to researchers and healthcare providers.
 
This shift allows for collaborative research efforts across institutions, enhancing the overall efficiency of genomic studies. Furthermore, the cost-effectiveness of cloud solutions is appealing to smaller organizations that may lack the infrastructure for extensive data analysis. As cloud adoption continues to grow, the market is anticipated to expand, with a projected increase in cloud-based genomic applications.

### Regulatory Support for AI in Healthcare

Regulatory support for the integration of AI in healthcare is a significant driver for the Artificial Intelligence in Genomics Market. Governments are increasingly recognizing the potential of AI technologies to improve patient outcomes and streamline genomic research. Initiatives aimed at establishing clear guidelines for the use of AI in genomics are being developed, which fosters innovation and encourages investment.
 
This supportive regulatory environment is likely to enhance the adoption of AI solutions in genomic applications, contributing to market growth. Analysts predict that as regulations evolve, the market could see a substantial increase in AI-driven genomic products and services.

### Advancements in Data Analysis Techniques

The Artificial Intelligence in Genomics Market is experiencing a surge in advancements related to data analysis techniques. The integration of machine learning algorithms enables researchers to process vast amounts of genomic data with unprecedented speed and accuracy. This capability is crucial as the volume of genomic data generated continues to grow exponentially.
 
For instance, the ability to analyze whole-genome sequencing data has improved significantly, allowing for more precise identification of genetic variants. As a result, the market is projected to witness a compound annual growth rate of over 30% in the coming years, driven by the demand for efficient data processing solutions.

### Growing Demand for Personalized Medicine

The shift towards personalized medicine is reshaping the landscape of the Artificial Intelligence in Genomics Market. Patients increasingly seek treatments tailored to their genetic profiles, which necessitates advanced genomic analysis. AI technologies facilitate this by enabling the identification of specific genetic markers associated with diseases.
 
Consequently, pharmaceutical companies are investing in AI-driven genomic solutions to enhance drug development processes. This trend is likely to propel the market forward, with projections indicating a potential market size of 15 billion dollars by 2026, as personalized medicine becomes a standard practice in healthcare.

### Increased Investment in Genomic Research

Investment in genomic research is a key driver for the Artificial Intelligence in Genomics Market. Governments and private entities are allocating substantial funds to enhance genomic studies, which in turn fuels the demand for AI technologies. For example, funding initiatives aimed at understanding genetic diseases and developing targeted therapies are on the rise.
 
This influx of capital not only supports research but also encourages collaborations between tech companies and research institutions. As a result, the market is expected to expand significantly, with estimates suggesting a valuation exceeding 20 billion dollars by 2027.

## Future Outlook

The  Artificial Intelligence in Genomics Market size is projected to reach USD 101.24 Billion by 2035, growing at a CAGR of 33.46%, driven by advancements in data analytics, personalized medicine, and genomic research.
By 2035, the Artificial Intelligence in Genomics Market is expected to be a cornerstone of genomic innovation and healthcare transformation.

**New opportunities:**

- Development of AI-driven genomic data analysis platforms Integration of AI in precision medicine workflows Creation of AI-based predictive models for disease susceptibility

By 2035, the market is expected to be a cornerstone of genomic innovation and healthcare transformation.

## Segment Insights

### By Application: Personalized Medicine (Largest) vs. Drug Discovery (Fastest-Growing)

In the Artificial Intelligence in Genomics Market, the application segment showcases significant diversity with varied market share distributions. Personalized Medicine holds the largest portion of 41%, reflecting a growing preference for tailored therapeutic approaches informed by genomics. Meanwhile, Drug Discovery is emerging as the fastest-growing segment, fueled by innovations that enhance the efficiency and accuracy of identifying potential drug candidates through computational models and AI techniques. Growth trends indicate that the demand for Personalized Medicine is steadily increasing, supported by advancements in [genetic testing](https://www.marketresearchfuture.com/reports/genetic-testing-market-2009)and the ongoing shift toward precision health. In contrast, the rapid development in Drug Discovery is driven by technological innovations that improve data analysis and predictive modeling, making it a key area for investment and research. These dynamics highlight the dual focus on individualized treatment options and the accelerated pace of drug development in response to evolving healthcare needs.

Applications: Personalized Medicine (Dominant) vs. Drug Discovery (Emerging)

Personalized Medicine stands out as the dominant application in the AI in Genomics Market, characterized by its focus on customizing healthcare strategies based on individual genetic profiles. This approach not only improves treatment efficacy but also reduces adverse effects by providing targeted therapies. As genomics becomes more integrated into clinical practice, its significance in shaping treatment paradigms continues to grow. On the other hand, Drug Discovery is emerging rapidly due to the increased reliance on AI technologies that streamline the discovery process, enhance computational drug design, and facilitate faster testing phases. This segment is gaining momentum as pharmaceutical companies seek to improve their R&D efficiency and bring novel therapies to market, highlighting the competitive edge that AI brings to drug development.

### By Technology: Machine Learning (Largest) vs. Deep Learning (Fastest-Growing)

In the Artificial Intelligence in Genomics Market, Machine Learning holds the largest share of 46% due to its extensive application in genomic data analysis, predictive modeling, and decision support systems. It has been instrumental in processing vast amounts of genomic data to uncover patterns and insights essential for personalized medicine. On the other hand, Deep Learning is rapidly gaining traction, particularly for its efficacy in pattern recognition and image analysis, which are crucial for interpreting genomic sequences and annotations. As genomics continues to evolve, the reliance on intelligent systems to interpret complex data sets is driving the expansion of these technologies. The growth trends in this segment are powered by the increasing availability of genomic data and advancements in computational power. Machine Learning has established itself as a staple in genomics, utilized for tasks ranging from variant calling to the identification of therapeutic targets. Conversely, Deep Learning's ability to automate feature extraction and enhance accuracy is making it a preferred choice for researchers. With the integration of AI in genomics becoming more pronounced, both segments are expected to witness sustained growth, spurred by innovations and heightened investments in genomic research initiatives.

Technology: Machine Learning (Dominant) vs. Deep Learning (Emerging)

Machine Learning is a dominant force in the Artificial Intelligence in Genomics Market, as it equips researchers and clinicians with tools to analyze and interpret complex genomic data. Its techniques such as decision trees and support vector machines have proven effective in differentiating between normal and mutated genes, thus facilitating early disease diagnosis and treatment planning. Meanwhile, Deep Learning is emerging as a powerful tool, particularly for analyzing unstructured data types like genomic images, where traditional methods fall short. By leveraging artificial neural networks, Deep Learning can learn intricate patterns in large datasets, making it invaluable for applications like genome-wide association studies. Together, these technologies complement each other, with Machine Learning providing a foundational framework while Deep Learning pushes the boundaries of what's possible in genomics.

### By End User: Pharmaceutical Companies (Largest) vs. Biotechnology Companies (Fastest-Growing)

In the Artificial Intelligence in Genomics Market, the distribution among end users indicates that pharmaceutical companies hold the largest market share of 44%, attributed to their extensive research and development capabilities and the substantial investments they make in genomic research. Following them, healthcare providers and research institutes contribute significantly, while biotechnology companies are on a rapid growth trajectory, leveraging AI advancements to enhance genomic solutions for precision medicine.

Pharmaceutical Companies (Dominant) vs. Biotechnology Companies (Emerging)

Pharmaceutical companies are dominant players in the Artificial Intelligence in Genomics Market, utilizing AI technologies to streamline drug discovery and personalize treatment plans through genomics. Their established infrastructure and R&D funding allow them to integrate sophisticated AI solutions effectively. On the other hand, biotechnology companies are emerging as key innovators, focusing on niche areas within genomics, such as genetic editing and synthetic biology. Their agility and focus on groundbreaking technologies position them as the fastest-growing segment in the Artificial Intelligence in Genomics Market, enabling them to capitalize on new opportunities and trends.

### By Deployment Mode: Cloud-Based (Largest) vs. Hybrid (Fastest-Growing)

In the Artificial Intelligence in Genomics Market, cloud-based deployment methods hold the largest share of 58% due to their scalability and flexibility, allowing organizations to leverage advanced computing resources without heavy upfront investments. In contrast, on-premises solutions cater to businesses that require stringent control over their data; however, they do not have the Artificial Intelligence in Genomics Market dominance of cloud options. Hybrid models are also gaining traction, providing an integrated approach that combines the benefits of both on-premises and cloud deployments.

Deployment Mode: Cloud-Based (Dominant) vs. Hybrid (Emerging)

Cloud-based deployment continues to be the dominant mode in the Artificial Intelligence in Genomics Market, as it offers essential advantages like efficient resource management, high scalability, and ease of access from any location. This facilitates rapid data analysis and minimizes infrastructure costs. Conversely, hybrid deployment is emerging as a preferred choice for organizations that seek a balanced approach, enabling them to utilize both cloud resources and on-premises capabilities. This combination not only enhances data security but also allows for seamless integration, leading to increased demand as companies aim to optimize their genomic research processes.

## Regional Market Share Analysis

North America leads in the Artificial Intelligence In Genomics Market size, accounting for over 22.22% of the global revenue in 2024, showcasing its dominance due to strong investments in health technology and research facilities. Europe follows closely,

Europe Artificial Intelligence In Genomics Market size was valued at USD 0.7 Billion in 2024, making it the second-largest regional market with a 16.54% share, reflecting robust research initiatives and collaborations among government and industry stakeholders.

- According to the Centers for Disease Control and Prevention, genomic sequencing and precision medicine initiatives continue expanding across the United States healthcare ecosystem. Increasing investments in biotechnology, AI-driven diagnostics, and large-scale genomic research programs are accelerating adoption of artificial intelligence technologies in genomics throughout North America.

South America, valued at 0.15 USD billion in 2024, is anticipated to grow to 1.75 USD billion by 2035, albeit with slower adoption rates due to less funding in technology. In Asia Pacific, a valuation of 0.5 USD billion in 2024 is expected to rise to 4.45 USD billion by 2035, supported by increasing investment in biotechnology and healthcare sectors, indicating significant growth potential. The Middle East and Africa begin with a valuation of 0.06 USD billion in 2024 and may reach 0.92 USD billion in 2035.

- The World Health Organization emphasizes growing demand for precision medicine and genomic innovation across European healthcare systems. Rising investments in genomic data infrastructure, collaborative research programs, and AI-supported diagnostics are strengthening Europe’s position as a major regional market for artificial intelligence in genomics applications.

This lower figure highlights the emerging market opportunities in AI-driven genomics which may be further enhanced by increased government support and global collaborations.

## Competitive Benchmarking

The Artificial Intelligence in Genomics Market has garnered significant attention over recent years as innovations in AI technology enable new possibilities in genomic research and analysis. The competitive landscape is characterized by a diverse array of players ranging from established biotech firms to emerging tech companies. These entities are increasingly leveraging artificial intelligence to enhance data interpretation, improve accuracy in genomic sequencing, and streamline workflows in genomic laboratories.
Companies are differentiating themselves not only through technological innovation but also by forming strategic partnerships, engaging in mergers and acquisitions, and expanding their service offerings to meet the evolving needs of researchers and healthcare institutions. As the demand for personalized medicine and genomic data analysis grows, the competitive dynamics will continue to evolve with an emphasis on cutting-edge research and application.
Thermo Fisher Scientific is a leading player in the Artificial Intelligence in Genomics Market, known for its robust portfolio of genomic solutions and advanced technologies. The company has established a strong presence in the Artificial Intelligence in Genomics Market by effectively integrating AI with its extensive tools for sequencing, genotyping, and molecular analysis. Thermo Fisher Scientific's strength lies in its ability to deliver comprehensive solutions that cater to various stages of the genomic research workflow, from sample preparation to data analysis.
By investing in research and development, the company has been able to enhance its capabilities in machine learning and data analytics, thus improving the accuracy and efficiency of genomic tests. Furthermore, its global reach and established relationships with research institutions and healthcare providers enable Thermo Fisher Scientific to maintain a steady position in the Artificial Intelligence in Genomics Market and continue driving advancements in genomic AI applications.
iCarbonX is an important biotechnology company based in Shenzhen, known for its integration of artificial intelligence with genomic and multi-omics data to provide personalized health insights. Established in 2015 by former BGI CEO Jun Wang, the company’s premier platform, Meum, employs AI to assess genomic, proteomic, and behavioral data, providing customized health recommendations. The organization specializes in creating AI-driven tools for data mining, predictive modeling, and visualization, establishing itself as a significant contributor to precision health and digital genomics.
Supported by prominent investors and strategic partnerships, iCarbonX has broadened its international footprint through initiatives such as the Digital Life Alliance, working alongside organizations like SomaLogic and PatientsLikeMe. The acquisition of Israel-based Imagu Vision Technologies has further enhanced its AI and image-processing capabilities, solidifying its position as a leader in the evolving landscape of AI in genomics.

## Recent News & Developments

Recent advancements in the Artificial Intelligence in Genomics Market highlight remarkable progress and creativity. Organizations such as Thermo Fisher Scientific and Illumina are enhancing their AI-driven platforms to improve genomic sequencing and analysis, with Illumina utilizing DRAGEN for faster variant calling and data interpretation.

In July 2023, Illumina introduced the Alliance for Genomic Discovery, a collaborative initiative involving deCODE genetics (an Amgen subsidiary), AbbVie, AstraZeneca, Bayer, and Merck. This partnership aims to co-fund whole-genome sequencing of 250,000 diverse samples for the purpose of drug target discovery.

Microsoft has been enhancing its involvement in the biotech sector, particularly through a partnership with 1910 Genetics in June 2023 to implement Azure Quantum Elements for AI-driven drug discovery. Additionally, Amgen’s deCODE genetics started utilizing NVIDIA’s BioNeMo supercomputer in early 2024 to develop extensive genomic models (“Freyja”) aimed at biomarker and target discovery.

In recent years, there has been a surge of interest in AI-powered genomics, particularly following the launch of Grail's Galleri multi-cancer early-detection blood test in late 2022, which represents a significant advancement in AI-driven diagnostic applications.

## Report Scope

| MARKET SIZE 2024 | 4.231(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 5.646(USD Billion) |
| MARKET SIZE 2035 | 101.24(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 33.46% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Illumina (US), Thermo Fisher Scientific (US), Bristol-Myers Squibb (US), GRAIL (US), IBM (US), Deep Genomics (CA), Freenome (US), XtalPi (CN), Genomatix (DE) |
| Segments Covered | Application, Technology, End User, Deployment Mode, Regional |
| Key Market Opportunities | Integration of advanced machine learning algorithms enhances genomic data analysis and personalized medicine. |
| Key Market Dynamics | Rising integration of artificial intelligence enhances genomic data analysis, driving innovation and competitive dynamics in the market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the projected market valuation of the Artificial Intelligence in Genomics Market by 2035?**
A: The market is projected to reach a valuation of 101.24 USD Billion by 2035.

**Q: What was the overall market valuation of the Artificial Intelligence in Genomics Market in 2024?**
A: The overall market valuation was 4.231 USD Billion in 2024.

**Q: What is the expected CAGR for the Artificial Intelligence in Genomics Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the market during the forecast period is 33.46%.

**Q: Which application segment had the highest valuation in 2024?**
A: The Genetic Testing application segment had the highest valuation at 1.023 USD Billion in 2024.

**Q: What are the leading technologies utilized in the Artificial Intelligence in Genomics Market?**
A: Leading technologies include Machine Learning, Deep Learning, and Natural Language Processing, with valuations of 1.5, 1.2, and 0.8 USD Billion respectively in 2024.

**Q: Which end user segment contributed the most to the market in 2024?**
A: Pharmaceutical Companies contributed the most, with a valuation of 1.269 USD Billion in 2024.

**Q: What is the valuation of the Cloud-Based deployment mode in 2024?**
A: The Cloud-Based deployment mode had a valuation of 1.694 USD Billion in 2024.

**Q: Who are the key players in the Artificial Intelligence in Genomics Market?**
A: Key players include Illumina, Thermo Fisher Scientific, and IBM, among others.

**Q: What is the valuation of the Personalized Medicine application segment in 2024?**
A: The Personalized Medicine application segment was valued at 1.067 USD Billion in 2024.

**Q: How does the market's growth potential appear in comparison to its current valuation?**
A: The market's growth potential appears substantial, with a projected increase from 4.231 USD Billion in 2024 to 101.24 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/artificial-intelligence-in-genomics-market-22233*